Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Overall, the majority of patients that contract the infection have a haematological malignancy as an underlying condition (>50% of cases).6 Looking specifically at the ICU patient population, however, information about the epidemiology of invasive aspergillosis is scarce, but data are emerging for this particular and unique setting.4
An overview of the SECURE trial for CRESEMBA (isavuconazole)
The SECURE trial
An overview of the VITAL trial for CRESEMBA (isavuconazole)
The VITAL trial
ARDS, acute respiratory distress syndrome; BMT, bone marrow transplant; COPD, chronic obstructive pulmonary disease; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycosis Study Group; HIV, human immunodeficiency virus; ICU, intensive care unit; TNF, tumour necrosis factor.
Prescribing Information for Cresemba (isavuconazole)
Cresemba (isavuconazole) 100mg hard capsules
Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion
Cresemba (Isavuconazole) 100mg hard capsules and Cresemba (Isavuconazole) 200mg powder for concentrate for solution for infusion
How to approach diagnostics
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020